Eupraxia Pharmaceuticals Inc 6-K, filed Apr 8, 2024
Eupraxia Pharmaceuticals Inc. (EPRX)
About this 6-K
Eupraxia Pharmaceuticals Inc filed this 6-K on April 8, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number 001-41923
EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s name)
201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968
(Address and telephone number of registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☐ Form 40-F ☒
INCORPORATION BY REFERENCE
Exhibit 99.1 of this Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-276586) and the registrant’s Registration Statement on Form S-8 (File No. 333-278534).
DOCUMENTS INCLUDED AS PART OF THIS REPORT
| Exhibit | ||
| 99.1 | Material Change Report, dated April 8, 2024 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Eupraxia Pharmaceuticals Inc. | ||||||
| Date: April 8, 2024 | By: | /s/ Bruce Cousins | ||||
| Name: Bruce Cousins | ||||||
| Title: President and Chief Financial Officer | ||||||
Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
| Item 1: | Name and Address of Company |
Eupraxia Pharmaceuticals Inc. (the “Company”)
201-2067 Cadboro Bay Rd.
Victoria, British Columbia
Canada, V8R 5G4
| Item 2: | Date of Material Change |
April 5, 2024
| Item 3: | News Release |
A news release announcing the material change was issued on April 5, 2024 through Globe Newswire and a copy was subsequently filed on SEDAR+.
| Item 4: | Summary of Material Change |
On April 5, 2024, the Company announced that trading of the Company’s common shares would begin on the Nasdaq Capital Market (“Nasdaq”), under the ticker symbol “EPRX”.
| Item 5.1: | Full Description of Material Change |
On April 5, 2024, the Company announced that trading of the Company’s common shares would begin on the Nasdaq, under the ticker symbol “EPRX”. The Company’s shares also continue to trade on the Toronto Stock Exchange under the ticker symbol “EPRX”.
| Item 5.2: | Disclosure of Restructuring Transactions |
Not applicable.
| Item 6: | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not applicable.
| Item 7: | Omitted Information |
Not applicable.
| Item 8: | Executive Officer |
For further information, please contact Bruce Cousins, President and Chief Financial Officer of the Company at 250-590-3968.
| Item 9: | Date of Report |
April 8, 2024